<!doctype html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <title>Geographic Summary of HTLV-1 Clinical Trials</title>
    <link rel="stylesheet" href="https://www.w3schools.com/w3css/5/w3.css">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Lato">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Montserrat">
    <link rel="stylesheet" href="htlv1_css.css">
    <link rel="stylesheet" href="https://unpkg.com/leaflet@1.9.4/dist/leaflet.css"
     integrity="sha256-p4NxAoJBhIIN+hmNHrzRCf9tD/miZyoHS5obTRR9BMY="
     crossorigin=""/>
     
<script src="https://unpkg.com/leaflet@1.9.4/dist/leaflet.js"
     integrity="sha256-20nQCchB9co0qIjJZRGuk2/Z9VM+kNiyxNV1lvTlZBo="
     crossorigin="">
</script>
<script src="https://ajax.googleapis.com/ajax/libs/jquery/3.7.1/jquery.min.js"></script>
    
<style>
body,h1,h2,h3,h4,h5,h6 {font-family: "Lato", sans-serif}
.w3-bar,h1,button {font-family: "Montserrat", sans-serif}
.fa-anchor,.fa-coffee {font-size:200px}
</style>

</head>
<body>
<header class="w3-container w3-light-grey w3-center" style="padding:80px 16px">
  <h1 class="w3-margin w3-xlarge">Geographic Summary of HTLV-1 Clinical Trials Across the Globe</h1>
</header>
<!-- Lot's of CSS Selectors below!-->

<div class="w3-row-padding w3-padding-64 w3-container">
    <div class="w3-content">
      <h3>What is HTLV-1?</h3>
      <h5 class="w3-padding-32">HTLV-1 (Human T-cell Lymphotropic Virus Type 1) is a retrovirus that infects T-cells and is associated with various diseases, including adult T-cell leukemia/lymphoma (ATLL) and tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM).</h5>
      <h3>What research is available on HTLV-1?</h3>
      <h5 class="w3-padding-32">Since the disease is relatively rare, there is not a large amount of research funding allocation to learning more about the virus and potential treatments. In the past two decades, there has been a moderate increase in the number of research studies that have been conducted on HTLV-1. However, funding for clinical research trials remains sparse. Since 2019, there have only been 6 HTLV-1 related clinical trials conducted across the globe.</h5>
      <h3>Where has clinical research on HTLV-1 been conducted?</h3>
      <h5 class="w3-padding-32">As the virus is endemic to certain world regions, specifically South America and Japan, there has traditionally been a higher proportion of research funded in those areas vs. others. As detailed in the maps below, over the past 5 years, Japan-based entities have funded the highest number of clinical trials, closely followed by Brazil and Iran and the US have each funded one trial.</h5>
    </div>
</div>
    <h1>Summary of HTLV-1 Clinical Trials (2020-2025)</h1>
    <!--<p> A geographic overview of research entities that have completed clinical trials on HTLV-1 from 2020 to 2025</p>
    <p> The maps below give a geographic illustration of the regions, countries and instutitions where the most recent HTLV-1 clinical research has been conducted.</p>-->
<div class="w3-padding-20 w3-container">
    <div class="w3-content">
        <h3>Japan</h3>
        <h5 class="w3-padding-10">2020: Human T-cell leukemia virus type 1 may invalidate T-SPOT.TB assay results in rheumatoid arthritis patients: A retrospective case-control observational study</h5>
        <h5 class="w3-padding-10">2022: Efficacy of Corticosteroid Therapy for HTLV-1-Associated Myelopathy: A Randomized Controlled Trial (HAMLET-P) </h5>
        <h5 class="w3-padding-10">2023: A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM)</h5>
        <h5 class="w3-padding-10">2023: Efficacy of l-Arginine treatment in patients with HTLV-1-associated neurological disease </h5>
        <h5 class="w3-padding-10"><a href="https://pubmed.ncbi.nlm.nih.gov/38430272/">2024: Multicenter, randomized, double-blind, placebo-controlled phase 3 study of mogamulizumab with open-label extension study in a minimum number of patients with human T-cell leukemia virus type-1-associated myelopathy</a></h5>
    </div>
</div>
<div id="map"></div>

<div class="w3-padding-20 w3-container">
    <div class="w3-content">
        <h3>Brazil</h3>
        <h5 class="w3-padding-10">2020: Effectiveness of virtual reality games for falls, postural oscillations, pain and quality of life of individual HAM/TSP: a randomized, controlled, clinical trial </h5>
        <h5 class="w3-padding-10">2020: Electromiography Study in the Respiratory Muscle Training in Human Lymphotropic Virus Type 1</h5>
        <h5 class="w3-padding-10">2021: Pilates Method in People With HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/​TSP)</h5>
        <h5 class="w3-padding-10"><a href="https://pubmed.ncbi.nlm.nih.gov/40327517/">2022: Darifenacin x Parasacral Transcutaneous Electric Nerve Stimulation for OAB in Patients Infected With Human T-Lymphotropic Virus 1</a></h5>
    </div>
</div>
    <div id="mapBrazil"></div>

<div class="w3-padding-20 w3-container">
    <div class="w3-content">
        <h3>Iran</h3>
        <h5 class="w3-padding-10"><a href="https://www.sciencedirect.com/science/article/abs/pii/S1043466624003296">2024: Effects of probiotics on clinical manifestations and inflammatory markers in HTLV-1-associated myelopathy/tropical spastic paraparesis</a></h5>
    </div>
</div>
    <div id="mapIran"></div>

<div class="w3-padding-20 w3-container">
    <div class="w3-content">
        <h3>United States</h3>
        <h5 class="w3-padding-10">2018*: Raltegravir for HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) </h5>
        <h5 class="w3-padding-10">2019*: Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/​Lymphoma</h5>
        <h5 class="w3-padding-10"><a href="https://pubmed.ncbi.nlm.nih.gov/34562313/">2021: Clinical trial of raltegravir, an integrase inhibitor, in HAM/TSP</a></h5>
    </div>
</div>
    <div id="mapMultiple"></div>

    <p>Last webpage text</p>

<div class="w3-container w3-blue-grey w3-center w3-opacity w3-padding-64">
    <h1 class="w3-margin w3-large">Project Site for The Javascripting Graduate Student, taught by Professor Zweibel. 2025.</h1>
</div>

<script>
$("h3").hover(function(){
  $(this).css("background-color", "lightgrey");
  }, function(){
  $(this).css("background-color", "transparent");
});
</script>
    <script src="testMap.js"></script>
    
<!--    <script - Unused array for prior version of map
    const mapMultiple = L.map('mapMultiple');
    mapMultiple.setView([39.4, -100.5], 4);

    L.tileLayer('https://tile.openstreetmap.org/{z}/{x}/{y}.png', {
    attribution: '&copy; <a href="https://www.openstreetmap.org/copyright">OpenStreetMap</a> contributors'
    })
    .addTo(mapMultiple);

    L.marker([40.848722217858395, -73.84460536206392],{
        title: "Montefiore Medical Center",
        })
    .addTo(mapMultiple)
    .bindPopup('Montefiore Medical Center<br> Bronx, NY')
    
    const data = {
        montefiore: {
            coordinates: [40.848722217858395, -73.84460536206392],
            title: "Montefiore Medical Center",
        },
        hopkins: {
            coordinates: [39.328, -76.620],
            title: "Johns Hopkins University/Sidney Kimmel Cancer Center",
        },
        bethesda: {
            coordinates: [39.0, -77.0],
            title: "National Institutes of Health Clinical Center",
        },
        columbus: {
            coordinates: [39.9612, -82.9988],
            title: "Ohio State University Comprehensive Cancer Center",
        }
    };

    </script> -->

<!--insert script for content.js here (I think this should have json file)-->
    </body>
</html>
